Trials / Completed
CompletedNCT06814860
Microenvironmental Trial of Classical Hodgkin Lymphoma in Adolescents
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 36 (actual)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna · Academic / Other
- Sex
- All
- Age
- 12 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
Background. Classical Hodgkin's lymphoma (cHL) in adolescents between 15 and 18 years shows a higher disease-related mortality and the overall prognosis is worse than both children and adults. Objectives. To investigate the immune checkpoint inhibitors (ICPI) therapeutic targets and specific T-regulatory and cytotoxic T-cell subsets, in the subgroup of adolescent cHL patients and to investigate their prognostic power. Methods: Retrieved formalin-fixed paraffin-embedded (FFPE) of adolescent patients diagnosed with cHL with available clinical and tested by immunohistochemistry the immune checkpoint molecules CTLA-4, LAG-3, PD-1 and PDL1 and the biological markers FOXP3 and CD8.
Conditions
Timeline
- Start date
- 2024-02-07
- Primary completion
- 2024-05-23
- Completion
- 2024-10-31
- First posted
- 2025-02-07
- Last updated
- 2025-02-07
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06814860. Inclusion in this directory is not an endorsement.